clinical trials for glp-1 obesity meds actively recruiting GLP-1R agonists: Full of hope, use with caution clinical trials for glp-1 obesity

Symptoms of low blood sugar may include dizziness or light-headedness, sweating, shakiness, blurred vision, slurred speech, weakness, anxiety, hunger, headache, irritability or mood changes, confusion or drowsiness, fast heartbeat, feeling jittery

For patients with heart failure or chronic kidney disease, SGLT2 inhibitors are generally preferred first, with GLP-1 agonists considered when SGLT2 inhibitors are contraindicated or not tolerated

Refrigeration after mixing is typically recommended to maintain optimal solution quality and extend usability

In addition, neither the stroke patient group nor the control group were treated with anti-diabetic drugs